March 24, 2023
AD/PD 2023 | Long-term follow up of LECIG use in Sweden
Levodopa-entacapone-carbidopa intestinal gel (LECIG) is a new treatment offered to patients with advanced Parkinson’s disease (PD), when oral levodopa use no longer provides adequate control of motor symptoms. Dag Nyholm, MD, PhD, Uppsala University, Uppsala, Sweden, discusses the latest nationwide registry data for LECIG, after three years of clinical experience in a cohort of patients with PD in Sweden.
May 31, 2022
Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
As Parkinson’s disease (PD) progresses, treatment needs to be adapted to maintain symptom control. Once patients develop advanced PD, an optimised regimen of oral and transdermal medications may no longer provide adequate relief of OFF periods and motor complications can emerge. At this point, patients may wish to consider a device-aided therapy (DAT) that provides continuous dopaminergic stimulation to help overcome these issues. Levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion is a recently developed DAT option.
March 31, 2021
Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
Patients in fluctuating stages of Parkinson’s disease (PD) require device-aided treatments. Continuous infusion of levodopa–carbidopa intestinal gel (LCIG) is a well-proven option in clinical practice. We now report the first clinical experience of levodopa–entacapone–carbidopa intestinal gel (LECIG) therapy.
December 17, 2016
Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study
The addition of oral entacapone to levodopa-carbidopa intestinal gel treatment leads to less conversion of levodopa to 3-O-methyldopa, thereby increasing levodopa plasma concentration. The objective of this study was to compare systemic levodopa exposure of the newly developed levodopa-entacapone-carbidopa intestinal gel after a 20% dose reduction with levodopa exposure after the usual levodopa-carbidopa intestinal gel dose in a randomized crossover trial in advanced Parkinson's disease patients.
January 13, 2004
Continuous dopaminergic stimulation in early and advanced Parkinson’s disease
Evidence from preclinical and clinical studies indicates that pulsatile stimulation of striatal dopamine receptors is a key factor in the development of levodopa-associated motor complications. Therefore, in the de novo patient it is believed that providing a more continuous dopaminergic stimulation from the start of antiparkinson therapy may prevent priming for motor fluctuations and dyskinesia. Conversely, in the more advanced patient who is already suffering from motor complications, it is believed that providing a more continuous stimulation may reverse the development of motor complications, enabling the patient to enjoy more stable benefits from therapy.